

CONTENTS

June 2018
Volume 17 no. 6

REVIEWS

395 Interleukin-6: designing specific therapeutics for a complex cytokine

Christoph Garbers, Sylvia Heink, Thomas Korn and Stefan Rose-John

Dysregulation of IL-6 signalling is associated with inflammatory and lymphoproliferative disorders, and several classes of therapeutics have been developed that target components of the IL-6 signalling pathway. This Review describes the progress made in recent years in inhibiting IL-6-signalling and analyses the advantages and disadvantages of these approaches.

413 Post-exposure treatments for Ebola and Marburg virus infections

Robert W. Cross, Chad E. Mire, Heinz Feldmann and Thomas W. Geisbert

Efforts towards developing post-exposure therapies for infections with filoviruses, particularly Ebola and Marburg viruses, increased substantially during the Ebola virus outbreak of 2013–2016. Geisbert and colleagues review the progress made on this front and discuss the challenges and opportunities for developing post-exposure therapies in the future.

435 RNA-modifying proteins as anticancer drug targets

P. Ann Boriack-Sjodin, Scott Ribich and Robert A. Copeland

Covalent modifications of RNA — mediated by RNA-modifying proteins (RMPs) — affect RNA stability and translation to proteins, and some of these RMPs have been implicated in cancer. Here, Copeland and colleagues review the current understanding of RNA modifications with a focus on mRNA methylation and assess the potential of RMPs as novel anticancer targets.

ADVERTISEMENT FEATURE

BIOPHARMA DEALMAKERS

In this edition, the features analyse the commercial landscape for infectious disease R&D, how to develop IP strategies and deals in the fibrosis field. The features follow the Review that finishes on p453 and were produced thanks to the commercial support of the organizations featured in the advertorial profiles.

Nature Reviews Drug Discovery (ISSN 1474-1776) is published monthly by Nature America, Inc. p, 1 New York Plaza STE 4500, New York NY 10004-1562, USA. US Periodicals postage paid at New York, NY and additional mailing post offices. US POSTMASTER: Send address changes to Nature America, Inc., Subscription Dept, 1 New York Plaza STE 4500, New York NY 10004-1562, USA.

Copyright © 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Printed in USA. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form (electronic or otherwise) without prior permission from permissions@nature.com.

www.nature.com/nrd

POWERPOINT SLIDES Figures and tables can be downloaded as PowerPoint files for use in presentations and for teaching.

E-ALERT SIGN-UP Get FREE monthly e-mail alerts to the content of this journal by registering online. Or sign up to receive the latest content as an RSS newsfeed by visiting www.nature.com/nrd

TWITTER Follow *Nature Reviews Drug Discovery* on Twitter for the latest news from the journal and beyond: @NatRevDrugDisc

ONLINE CORRESPONDENCE Comments from readers about our articles. All correspondence will be highlighted on the table of contents and on e-mail alerts.


COMPETING INTERESTS POLICY Authors of articles in *Nature Reviews Drug Discovery* are required to declare any competing interests. For details, please see www.nature.com/authors/policies/competing.html


ADVANCE ONLINE PUBLICATION We operate an advance online publication (AOP) service for authors and readers to view the latest articles published online ahead of print.

2-YEAR IMPACT FACTOR 57.000

2-YEAR MEDIAN 38

For more information on journal metrics, please see www.nature.com/ngp_/company_info/journal_metrics.html






Immunotherapeutic strategies for sepsis p381

- 379 COMMENT**
Accelerated approval of medicines: fit for purpose?
Alasdair Breckenridge and Lawrence Liberti

NEWS & ANALYSIS

- 381 NEWS**
Sepsis researchers set sights on immunotherapeutic strategies
 Two immune-boosting strategies have independently indicated promise in sepsis clinical trials, after years of failures with anti-inflammatories in this same space. Will it be enough to take sepsis drug development out of 'critical condition'?
- 383**
When drugs unintentionally affect gut bugs
 Many drugs unexpectedly influence the human gut microbiome, showed a recent study, prompting questions about toxicity assays, clinical implications and repurposing opportunities.
- 385 News in brief**
 BACE failures lower AD expectations, again | On the origin of transformative drugs | FDA approves first-in-class SYK inhibitor



NOW PUBLISHING CONTENT


A new open access journal for the chemical sciences from Nature Research


Communications Chemistry publishes high-quality primary research articles, reviews and commentary in all areas of the chemical sciences. Papers published in the journal represent significant advances that bring new insight to a specialized area of research.

All papers are handled by experienced in-house professional editors supported by an expert Editorial board.

Submit your research today and benefit from:

- Thorough peer review
- Fast decision process
- High Nature editorial standards
- High visibility
- CC-BY open access as standard





CANCER
RNA-modifying proteins as drug targets

Interleukin-6
Designing specific therapeutics for a complex cytokine

► COVER: 'RNA-modifying proteins as drug targets' by Susanne Harris, inspired by the Review on p435.

MEET THE EDITORS



PETER KIRKPATRICK



SARAH CRUNKHORN



MEGAN CULLY



M. TERESA VILLANUEVA



KATIE KINGWELL

NEWS & ANALYSIS

AN AUDIENCE WITH...

386

Norbert Bischofberger

Norbert Bischofberger, former CSO of Gilead, discusses antiviral opportunities, Gilead's pivot to oncology and the need for a societal discussion of drug costs.

FROM THE ANALYST'S COUCH

389

What drives site performance in clinical trials?

This article highlights results from a comprehensive study of the performance of clinical trial sites, which could help companies understand the underlying drivers of success.

RESEARCH HIGHLIGHTS

391

NEURODEGENERATIVE DISORDERS Rescuing mitochondrial motility

392

NEUROSCIENCE Reconnecting the brain after injury


393

CANCER Personalized cancer vaccines hit the spot

394

IN BRIEF Cancer | Autoimmune disease | Liver disease | Cancer

ANTIBACTERIAL DRUGS Disrupting MRSA 'persisters'



392

EDITORIAL & PRODUCTION OFFICE

The Campus, 4 Crinan Street, London N1 9XW, UK
Tel: +44 (0)20 7833 4000 | Email: nrdd@nature.com
www.nature.com/nrd

CHIEF EDITOR Peter Kirkpatrick

SENIOR EDITORS Sarah Crunkhorn, Megan Cully, M. Teresa Villanueva

ASSOCIATE EDITOR (NEWS) Katie Kingwell

COPY EDITOR Stephanie Wills

SENIOR ART EDITOR Susanne Harris

PRODUCTION EDITOR Melanie Gardeur

JOURNAL ASSISTANTS Owen Stretton, Sivanjaa Manoj

SENIOR EDITORIAL ASSISTANT Ashleigh Carver

CROSS-JOURNAL EDITORS Katharine Wrighton (Team Leader), Caroline Barranco and Isobel Leake (Seniors), Conor Bradley, Grant Otto and Shimona Starling (Associates)

PROOFREADING SUPERVISOR Carrie Hardy

EDITORIAL ADMINISTRATION MANAGER Rebecca Cromie

MANAGING PRODUCTION EDITOR Emma Carter

SENIOR PRODUCTION EDITOR Simon Fenwick

ASSISTANT PRODUCTION EDITOR Kate Snowdon

PRODUCTION CONTROLLER Natalie Smith

OFFICE AND ADMINISTRATION MANAGER Laura Lee

EXECUTIVE EDITOR Arianne Heinrichs

NATURE EDITORIAL DIRECTOR Ritu Dhand

EDITORIAL DIRECTOR Alison Mitchell

CUSTOMER SERVICES www.nature.com/help

PERSONAL SUBSCRIPTIONS subscriptions@nature.com

REPRINTS www.nature.com/reprints

ADVERTISING & SPONSORSHIP www.nature.com/advertising

SITE LICENCES www.nature.com/libraries/site_licenses/index.html

PRESS OFFICE press@nature.com

MARKETING marketing@nature.com

MANAGEMENT OFFICES

SPRINGER NATURE LONDON

The Campus, 4 Crinan Street, London, N1 9XW, UK.
Tel: +44 (0)20 7833 4000

SPRINGER NATURE NEW YORK

One New York Plaza, Suite 4500, New York, NY 10004-1562, USA. Tel: +1 212 726 9200

SPRINGER NATURE ASIA-PACIFIC

Shiroyama Trust Tower 5F, 4-3-1 Toranomon, Minato-Ku, Tokyo 105-6005 Japan. Tel: +81 3 4533 8050

A list of other offices can be found at www.nature.com/npg_/contact/offices.html